Title
Viability enrichment of final drug product using counter-flow centrifugation
Conference Dates
February 6 – 10, 2022
Abstract
The CAR-T manufacturing process is sensitive to donor variability, which impacts the final product quality, including cell viability. A counterflow centrifugation cell washer offers a solution to this problem by utilizing physical differences between viable and non-viable cells to elutriate the smaller and less dense non-viable cell population while preserving the viable cells population in the washing chamber. The Thermofisher CTS Rotea Counterflow Centrifugation System was evaluated against a dead-end centrifuge to wash low viability donors at the end of cell culture. The counterflow centrifuge cell washer improved the viability of the final drug product by 15% against the dead-end centrifuge washer. The ability to enrich low viability cell cultures during final harvest mitigates the risk of low viability final drug products and facilitates the stability of product quality.
Recommended Citation
Jonathan Lim, Christine Cezar, Ivie Aifuwa, and Vincent Couming, "Viability enrichment of final drug product using counter-flow centrifugation" in "Advancing Manufacture of Cell and Gene Therapies VII", Sharon Brownlow, Cell & Gene Therapy Catapult, UK; Sean Palecek, University of Wisconsin, USA; Damian Marshall, Achilles Therapeutics, UK; Fernanda Masri, Cell & Gene Therapy Catapult, UK Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/cellgenetherapies_vii/24